scispace - formally typeset
P

Phyllis Carosone-Link

Researcher at University of Colorado Denver

Publications -  26
Citations -  2942

Phyllis Carosone-Link is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Quantitative trait locus & Candidate gene. The author has an hindex of 17, co-authored 26 publications receiving 2275 citations. Previous affiliations of Phyllis Carosone-Link include Boston Children's Hospital & University of Colorado Boulder.

Papers
More filters
Journal ArticleDOI

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Ting Shi, +138 more
- 02 Sep 2017 - 
TL;DR: In this paper, the authors estimated the incidence and hospital admission rate of RSV-associated acute lower respiratory infection (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions.
Journal ArticleDOI

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

Harish Nair, +52 more
- 03 Dec 2011 - 
TL;DR: The role of influenza in childhood mortality from ALRI is estimated by combining incidence estimates with case fatality ratios from hospital-based reports and identifying studies with population-based data for influenza seasonality and monthly ALRI mortality.
Journal ArticleDOI

Genetic structure of the LXS panel of recombinant inbred mouse strains: a powerful resource for complex trait analysis.

TL;DR: The set of LXS recombinant inbred strains is a new and exceptionally large mapping panel that is suitable for the analysis of complex traits with comparatively high power and should prove to be of great utility in modeling the genetics of complex diseases in human populations.
Journal ArticleDOI

Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.

TL;DR: Using a test-negative case–control design with RSV molecular detection, palivizumab is shown to prevent RSV hospitalizations and intensive care unit admissions in high-risk infants.